Several studies showed that inhibition of ACVR2 signaling by systemically administered sACVR2B or antibodies against the receptor not only markedly improved muscle mass and function in cancer hosts, but also prolonged survival [10,11,12,13,146]. The gene discussed is ACVR2A; the disease is cancer.